Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biotype-assigned Augmentation Approach in Resistant Late-Life Depression (BAARD): a Randomized Controlled Trial

NCT07810738 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07810738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07810738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biotype-assigned Augmentation Approach in Resistant Late-Life Depression (BAARD): a Randomized Controlled Trial
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
September 15, 2029
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression - major depressive disorder, late life treatment resistant depression, treatment resistant depression